LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at SVB Leerink

SVB Leerink began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note published on Monday morning, Marketbeat reports. The brokerage issued an outperform rating and a $32.00 target price on the stock.

Other equities research analysts have also issued research reports about the company. Citigroup began coverage on LENZ Therapeutics in a research note on Wednesday, April 10th. They issued a buy rating and a $34.00 price target for the company. Piper Sandler started coverage on LENZ Therapeutics in a research note on Wednesday, March 27th. They set an overweight rating and a $28.00 target price on the stock. Finally, William Blair started coverage on LENZ Therapeutics in a research note on Monday. They issued an outperform rating for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, LENZ Therapeutics currently has an average rating of Buy and a consensus price target of $31.33.

LENZ Therapeutics Price Performance

Shares of NASDAQ LENZ opened at $17.70 on Monday. The firm has a market capitalization of $147.30 million, a PE ratio of -1.13 and a beta of 0.20. LENZ Therapeutics has a 1 year low of $14.07 and a 1 year high of $29.82.

Insider Transactions at LENZ Therapeutics

In other news, Director Ra Capital Management, L.P. purchased 998,009 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The stock was bought at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the purchase, the director now owns 3,319,339 shares in the company, valued at $49,889,665.17. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 38.40% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.